Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Right, so ABDX finally put a media post out
https://www.linkedin.com/posts/abingdon-health_london-stock-exchange-london-stock-exchange-activity-7178041844059021313-DZLH?utm_source=share&utm_medium=member_desktop
Liked by Yannick Namia, CEO of our new investment
https://www.linkedin.com/in/yannick-namia/
Thanks Muck..
Thanks Ant, but nobody should look to me. I just post stuff I find, and my own thoughts, much of which may be irrelevant or rubbish!
But in that vein. and in the short term..
IMO this is being held back because the market is concerned about a raise. Regardless of what I think about that, a Director buy would help massively. It would show confidence in the business and indicate that no discounted raise in which they might otherwise participate is on the horizon.
Salistick FDA approval would spark interest from the many out there who think that is our one and only product.
I think we will be launching another test in boots in the pretty near future (weeks according to Crest Medical)
Muck, I think we all look to you..
So in your opinion what is it going to take to get this share moving north?
PW - thanks for posting the article, which helps describe the scale of the STI problem.
I haven't been able to shake the thought that somehow these new partners might have come through Senzo. This latest RNS says we have been working with them for 12 months, we announced the Senzo partnership almost 12 months ago to the day, and both the new partners and Senzo are based in the US.
https://www.senzo.com/newsroom/senzo-and-abingdon-health-enter-into-strategic-partnership
So this might also be interesting. Its a blog from Senzo about STI's which again details the scale of the problem and highlights that getting LFT sensitivity levels up when looking at STI conditions has been the main headwind in development. Of course, the whole point of Senzo is to increase sensitivity to PCR levels through its ALF tech.
https://static1.squarespace.com/static/63174674e5302f1a8f9e9dbc/t/659ae1c8fc1f77528ed44d4b/1704649165514/FDX+-+STI%28s%29.pdf
It does worry me that I can't find anything about our new partners, and nor have ABDX put out anything on their media feeds about this news so they're not screaming it from the rooftops - I have written to ABDX to see if they can give me anything more. But if we are looking at an LFT for STI's that meets required sensitivity thresholds then the market looks massive. And of course, by buying into a US based company we are getting a foothold in that jurisdiction.
I think the latter also.
He’s essentially making a growth acquisition from cash flow, without a raise. The fact he feels able to do that, just a week or so after confirming no raise expectation in 2024 and given his laser focus on cash flow break even, strengthens my belief that current revenues and forecasts are more than just robust.
I agree with your assessment teraferma - all looking quietly positive here now.
I would imagine it's the latter.
CY is no mug, he will be looking for a return on that investment, the fact that he's taken a director role as well, suggests to me that he thinks there is significant potential here.
Another positive for ABDX
This is interesting!
New At-Home STI Test Could Help Stop the Spread of Infection
https://www.scientificamerican.com/article/new-at-home-sti-test-could-help-stop-the-spread-of-infection/
The SP at close might give us a clue to which scenario is most likely occurring?
True, assuming the £500k all relates to future cost, and not cost already accrued.
Either Yates has been forced to take equity because there’s no cash, or he wants to take equity. If the latter, then it suggests strongly that he sees real growth potential in the project and expects it to accelerate progress to cash break even and beyond
On the face of it this sounds great. However, the company will be incurring cash costs to generate up to £500,000 in fees that will be paid for in shares in a company that’s not been around very long and for which there is an absence of financial information. How does this help in getting ABDX to a cash flow positive position?
Don’t really know what to make of this - scattergun thoughts are;
I can find nothing about Devyn LLC, Find Out From Home LLC, or Yannick Namia, which is odd.
The “LLC” suggests they’re US companies. That’s been a real growth area for us.
A £500k stake for 23% values FOFH LLC at over £2m. Not bad for a new unproven enterprise.
Are we investing because we want to, or because they can’t pay the fee? Great if the former - suggests real enthusiasm and potential.
I’m wondering if these new tests might be molecular or based on Senzo ALT tech
Honestly, on the face of it it looks great, but it’s difficult to add colour because there’s little else to go on.
As an aside, it’s interesting they brought the interims forward only to announce a succession of news thereafter.
Exactly. More positive news today. All building nicely at ABDX, albeit slowly....
* Four sexually transmitted disease lateral flow self-tests complete design freeze.
* Exclusive global manufacturing plus UK and European distribution rights via strategic partnership with USA-based Find Out From Home LLC.
Good luck, Brighty
There’s been a constant flow of positive news lately which is building a momentum. They’re building a solid base and things are looking very good atm… future looks very bright here.
Some momentum here at last
Yup. We’ve spent the last couple of years rebuilding on a prudent fee for service model, diligently growing our quality customer base. Through 2024 we will see more and more customers commercialising and requiring manufacture. That hopefully will produce a regular and growing annuity income from which further growth can be funded.
This thing sells itself imo. We just need more investors to look under the bonnet, but I’m happy to keep accumulating until they do.
God, I love this company. Quietly beavering away. Confidently disregarding the need for silly hype other would-be if they could -be companies resort to. Abingdon have dusted off past adversity, they clearly know where they are going, have outstanding expertise in commercialising and are innovating a whole new contemporary industry with few competitors at this point. I can't believe how far they have come and us LT shareholders are in an incredible position to gain from this ridiculous share price at the moment. Huge thanks to Muck165 and others for bringing all of this to light. Patience will be rewarded here. No doubt about it at all in my mind.
Wow, I think the vitamin D and iron deficiency rapid tests probably have even more marketability than the pregnancy test to be honest. Especially of interest to women who can be concerned over iron levels during different times of their life. We are all more concerned about vitamin D levels now too since covid. I take vitamin D every day.
A bit more colour to the ABDX proposition
https://www.abingdonsimplytest.com/own-brand-diagnostics-products-navigating-challenges/
ABDX certainly now pushing this OEM/private label as a new service to retailers
https://www.abingdonsimplytest.com/knowledge-centre/private-own-label-solutions/
This one, from the Co-owner and Director of Crest Medical makes for interesting, and potentially exciting, reading.
“ Delighted to have developed and worked with Abingdon Health plc and Boots UK on these two diagnostic tests … keep an eye out over the next few weeks for the next launch of a revolutionary test!!”
Does he mean another test in conjunction with ABDX - fair bet I think.
https://www.linkedin.com/posts/matthew-courtney-5ab14879_boots-to-sell-its-first-own-brand-self-tests-activity-7176600829678755841-nZVW?utm_source=share&utm_medium=member_desktop
Thanks gotreal.
From the RNS: "Diagnostic tests are another great addition to the Crest Medical portfolio as we look to expand further and deepen our partnership with Boots. Abingdon Health are at the forefront of this expansion and we are thrilled to be partnering with a company who are leaders in lateral flow diagnostics."
It suggests to me that Crest are a strategic supplier to Boots who probably, at some point, rationlised thier supply chain to a few key suppliers and part of the agreement was that Boots would only procure through them for certain types of products. Not an unusual arrangement in big corporates as the amount of red tape that has to be gone through to set up a new supplier can take literally years. I was involved in one with a large telco that took 3.5 years.